These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 29867488)

  • 1. Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
    Peres FF; Lima AC; Hallak JEC; Crippa JA; Silva RH; Abílio VC
    Front Pharmacol; 2018; 9():482. PubMed ID: 29867488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
    Elsaid S; Kloiber S; Le Foll B
    Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats.
    Peres FF; Levin R; Suiama MA; Diana MC; Gouvêa DA; Almeida V; Santos CM; Lungato L; Zuardi AW; Hallak JE; Crippa JA; Vânia D; Silva RH; Abílio VC
    Front Pharmacol; 2016; 7():343. PubMed ID: 27733830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of cannabinoids for movement disorders.
    Kluger B; Triolo P; Jones W; Jankovic J
    Mov Disord; 2015 Mar; 30(3):313-27. PubMed ID: 25649017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
    Sonego AB; Prado DS; Vale GT; Sepulveda-Diaz JE; Cunha TM; Tirapelli CR; Del Bel EA; Raisman-Vozari R; Guimarães FS
    Brain Behav Immun; 2018 Nov; 74():241-251. PubMed ID: 30217539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.
    Gomes FV; Del Bel EA; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():43-7. PubMed ID: 23791616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
    Zuardi AW
    Braz J Psychiatry; 2008 Sep; 30(3):271-80. PubMed ID: 18833429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
    Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and side effects of cannabidiol, a Cannabis sativa constituent.
    Bergamaschi MM; Queiroz RH; Zuardi AW; Crippa JA
    Curr Drug Saf; 2011 Sep; 6(4):237-49. PubMed ID: 22129319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.
    de Mello Schier AR; de Oliveira Ribeiro NP; Coutinho DS; Machado S; Arias-Carrión O; Crippa JA; Zuardi AW; Nardi AE; Silva AC
    CNS Neurol Disord Drug Targets; 2014; 13(6):953-60. PubMed ID: 24923339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological Aspects of Medical Use of Cannabidiol.
    Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
    CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From
    Cassano T; Villani R; Pace L; Carbone A; Bukke VN; Orkisz S; Avolio C; Serviddio G
    Front Pharmacol; 2020; 11():124. PubMed ID: 32210795
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabidiol, neuroprotection and neuropsychiatric disorders.
    Campos AC; Fogaça MV; Sonego AB; Guimarães FS
    Pharmacol Res; 2016 Oct; 112():119-127. PubMed ID: 26845349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Cannabidiol a Promising Substance for New Drug Development? A Review of its Potential Therapeutic Applications.
    Noreen N; Muhammad F; Akhtar B; Azam F; Anwar MI
    Crit Rev Eukaryot Gene Expr; 2018; 28(1):73-86. PubMed ID: 29773016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
    Moreira FA; Guimarães FS
    Eur J Pharmacol; 2005 Apr; 512(2-3):199-205. PubMed ID: 15840405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test.
    Almeida V; Levin R; Peres FF; Niigaki ST; Calzavara MB; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Mar; 41():30-5. PubMed ID: 23127569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol attenuates aggressive behavior induced by social isolation in mice: Involvement of 5-HT1A and CB1 receptors.
    Hartmann A; Lisboa SF; Sonego AB; Coutinho D; Gomes FV; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109637. PubMed ID: 31054943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.